Opicapone (Ongentys) - A COMT Inhibitor for Parkinson ' s Disease

Date: January 11, 2021 Issue #:  1615Summary:  The FDA has approved opicapone (Ongentys– Neurocrine), a peripherally-acting reversible catechol-O-methyltransferase (COMT) inhibitor, for oral use as an adjunct to carbidopa/levodopa in adults with Parkinson’s disease (PD) who experience " off " episodes. It is the third COMT inhibitor to be approved for this indication; tolcapone (Tasmar, and generics) and entacapone (Comtan, and generics) were approved earlier. Opicapone has been available in Europe since 2016.
Source: The Medical Letter - Category: Drugs & Pharmacology Authors: Tags: Apokyn Apomorphine Carbidopa/levodopa Comtan Dopamine Entacapone Epinephrine Inbrija istradefylline Kynmobi Movapo Nourianz Ongentys opicapone Parkinson ' s disease Phenelzine Rytary selegeline Stalevo Tasmar To Source Type: research